News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Media
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsShortsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Radiation Oncology|
Surgery
Advertisement

Ira Klein, MD, FACP

Advertisement

Articles by Ira Klein, MD, FACP

Cancer Care and Accountable Care Organizations: The Unknown Patient Experience Landscape

ByMichael Kolodziej, MD, FACP,Ira Klein, MD, FACP,Lonny Reisman, MD, FACC,Nancy Kotchko
October 15th 2013

ACOs can provide the structure, but it’s up to the stakeholders to establish mutually agreeable goals for this new care delivery model. Achieving these goals will require a different set of dialogues and conversations among stakeholders, and patients and their advocates must have seats at the table.

Advertisement

Latest Updated Articles

  • Cancer Care and Accountable Care Organizations: The Unknown Patient Experience Landscape
    Cancer Care and Accountable Care Organizations: The Unknown Patient Experience Landscape

    October 15th 2013



Advertisement
Advertisement

Trending on CancerNetwork

1

FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC

2

TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

3

FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer

4

FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer

5

138 HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib Versus Placebo Added to Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us